Search research articles
Contact Us
Filters
Showing results (211-220 of 418) with videos related to
Page
of 42
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 23, 2026
The Randomized Phase 2 ARC-9 Study of Etrumadenant-Based Therapy vs Regorafenib in Patients with Previously Treated Metastatic Colorectal Cancer
Michael Cecchini, Sae-Won Han, Soohyeon Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 14, 2019
Activity and Safety of Palbociclib in Patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Biomarker-driven Phase II Study
Maud Toulmonde, Jean-Yves Blay, Olivier Bouche, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 6, 2022
Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study
David M O'Malley, Giovanni Mendonca Bariani, Philippe A Cassier, et al.
Cancer
|
November 3, 2011
Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas
Antoine Italiano, Angela Cioffi, Nicolas Penel, et al.
Cancer
|
April 17, 2013
Sorafenib in patients with progressive epithelioid hemangioendothelioma: a phase 2 study by the French Sarcoma Group (GSF/GETO)
Christine Chevreau, Axel Le Cesne, Isabelle Ray-Coquard, et al.
Gynecologic Oncology
|
January 23, 2025
Pembrolizumab in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) and non-MSI-H/non-dMMR advanced endometrial cancer: Phase 2 KEYNOTE-158 study results
David M O'Malley, Giovani M Bariani, Philippe A Cassier, et al.
Cancers
|
October 23, 2020
Novel Therapeutic Insights in Dedifferentiated Liposarcoma: A Role for FGFR and MDM2 Dual Targeting
Bérengère Dadone-Montaudié, Audrey Laroche-Clary, Aline Mongis, et al.
Scientific Reports
|
November 4, 2025
Prognostic prediction in soft-tissue sarcomas using deep learning and digital pathology of tumor and margin areas
Audrey Michot, Van-Linh Le, Jean-Michel Coindre, et al.
BMC Cancer
|
October 12, 2018
Prognostic and predictive factors for angiosarcoma patients receiving paclitaxel once weekly plus or minus bevacizumab: an ancillary study derived from a randomized clinical trial
Loïc Lebellec, François Bertucci, Emmanuelle Tresch-Bruneel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 31, 2023
Better than RECIST and Faster than iRECIST: Defining the Immunotherapy Progression Decision Score to Better Manage Progressive Tumors on Immunotherapy
Younes Belkouchi, Hugues Talbot, Nathalie Lassau, et al.
Page
of 42
Search research articles
Search
Showing results (211-220 of 418) with videos related to
Sort By:
Page
of 42
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 23, 2026
The Randomized Phase 2 ARC-9 Study of Etrumadenant-Based Therapy vs Regorafenib in Patients with Previously Treated Metastatic Colorectal Cancer
Michael Cecchini, Sae-Won Han, Soohyeon Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 14, 2019
Activity and Safety of Palbociclib in Patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Biomarker-driven Phase II Study
Maud Toulmonde, Jean-Yves Blay, Olivier Bouche, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 6, 2022
Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study
David M O'Malley, Giovanni Mendonca Bariani, Philippe A Cassier, et al.
Cancer
|
November 3, 2011
Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas
Antoine Italiano, Angela Cioffi, Nicolas Penel, et al.
Cancer
|
April 17, 2013
Sorafenib in patients with progressive epithelioid hemangioendothelioma: a phase 2 study by the French Sarcoma Group (GSF/GETO)
Christine Chevreau, Axel Le Cesne, Isabelle Ray-Coquard, et al.
Gynecologic Oncology
|
January 23, 2025
Pembrolizumab in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) and non-MSI-H/non-dMMR advanced endometrial cancer: Phase 2 KEYNOTE-158 study results
David M O'Malley, Giovani M Bariani, Philippe A Cassier, et al.
Cancers
|
October 23, 2020
Novel Therapeutic Insights in Dedifferentiated Liposarcoma: A Role for FGFR and MDM2 Dual Targeting
Bérengère Dadone-Montaudié, Audrey Laroche-Clary, Aline Mongis, et al.
Scientific Reports
|
November 4, 2025
Prognostic prediction in soft-tissue sarcomas using deep learning and digital pathology of tumor and margin areas
Audrey Michot, Van-Linh Le, Jean-Michel Coindre, et al.
BMC Cancer
|
October 12, 2018
Prognostic and predictive factors for angiosarcoma patients receiving paclitaxel once weekly plus or minus bevacizumab: an ancillary study derived from a randomized clinical trial
Loïc Lebellec, François Bertucci, Emmanuelle Tresch-Bruneel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 31, 2023
Better than RECIST and Faster than iRECIST: Defining the Immunotherapy Progression Decision Score to Better Manage Progressive Tumors on Immunotherapy
Younes Belkouchi, Hugues Talbot, Nathalie Lassau, et al.
Page
of 42